EMMA Vienna 2017 | What is the PCROWD study, and how does knowledge in myeloma biology help with new treatments?
Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA talks about the importance of understanding the disease biology of myeloma. She begins by talking about the PCROWD study, which patients within the US currently have the opportunity to join and be a part of. The idea of this study is that a large group of patients will provide samples, and through blood and bone marrow biopsies of these large data sets, biomarkers that predict disease progression can be identified. The larger the number of samples, the better the results. Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria.
This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.
